NewAmsterdam Pharma Company (NAMS) financial statements
NewAmsterdam Pharma Company reported revenue of $23M in fiscal 2025, down 39.7% a year over 3 years.
Net income was -$204M.
Free cash flow was -$148M.
The diluted share count rose 979% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from NewAmsterdam Pharma Company's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $103M | $14M | $46M | $23M |
| Research and development | $29M | $87M | $159M | $151M | $142M |
| Selling, general and admin | $6M | $20M | $38M | $70M | $106M |
| Operating income | -$35M | -$4M | -$183M | -$176M | -$226M |
| Interest expense | $411,000 | $287,000 | — | — | — |
| Pre-tax income | -$42M | -$23M | -$177M | -$242M | -$204M |
| Income tax | — | — | $27,000 | -$1,000 | — |
| Net income | -$42M | -$23M | -$177M | -$242M | -$204M |
| EPS (diluted) | -$3.81 | -$1.19 | -$2.15 | -$2.56 | -$1.72 |
| Diluted shares | 11M | 19M | 82M | 94M | 118M |
| Operating margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Net margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
Balance sheet
Fiscal years, from NewAmsterdam Pharma Company's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | $468M | $340M | $834M | $636M |
| Total current assets | — | $478M | $347M | $863M | $676M |
| Property, plant and equipment | — | $34,000 | $46,000 | $242,000 | $383,000 |
| Total assets | — | $478M | $347M | $865M | $769M |
| Total current liabilities | — | $36M | $50M | $107M | $86M |
| Total liabilities | — | $48M | $59M | $107M | $86M |
| Shareholders' equity | -$114M | $430M | $288M | $758M | $683M |
| Net debt | — | -$468M | -$340M | -$772M | -$490M |
Cash flow
Fiscal years, from NewAmsterdam Pharma Company's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$30M | $11M | -$141M | -$159M | -$148M |
| Capital spending | $24,000 | $221,000 | $24,000 | $672,000 | $246,000 |
| Free cash flow | -$30M | $10M | -$141M | -$159M | -$148M |
| Stock-based compensation | $1M | $4M | $25M | $34M | $59M |
| Free cash flow margin | — | 10.2% | -1002.4% | -349.5% | -657.8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NAMS.
Open NAMS in InvestinglyQuestions
What was NewAmsterdam Pharma Company's revenue in 2025?
$23M in fiscal 2025, from its 10-K filing.
How much free cash flow does NewAmsterdam Pharma Company generate?
-$148M in fiscal 2025 (operating cash flow minus capital spending).
From NewAmsterdam Pharma Company's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.